Celgene dives 10% after ditching key drug

The once high-profile drug was expected to bring in as much as $2.4 billion in peak revenue.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X